CTOs on the Move

VentriFlo

www.ventriflo.com

 
The VentriFlo True Pulse Pump is a novel, truly pulsatile blood pumping system designed to achieve superior outcomes, reduce costs and improve safety for pediatric & adult patients who require cardiopulmonary support during surgery or in the ICU.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

VentriFlo raised $10M on 09/20/2019

Similar Companies

Visiogen

Visiogen, Inc. is a Irvine, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Medicom

Medicom is a Brooklyn, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Avinger

Avinger, Inc. is a commercial-stage medical device company that designs, manufactures and sells image-guided, catheter-based systems for the treatment of patients with peripheral artery disease (PAD). PAD is characterized by a build-up of plaque in the arteries that supply blood to the arms and legs. The company’s mission is to radically change the way vascular disease is treated through the introduction of products based on its lumivascular platform, the only intravascular image-guided system of therapeutic catheters available in this market. Avinger’s current lumivascular products include the Lightbox imaging console, the Ocelot family of catheters, which are designed to penetrate total arterial blockages, known as chronic total occlusions, or CTOs, and Pantheris, the first-ever image- guided atherectomy device, designed to precisely remove arterial plaque in PAD patients.

Boekel Scientific

Boekel Scientific is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.

JenaValve

JenaValve Technology, Inc., based in Irvine, California and Munich, Germany develops, manufactures and markets transcatheter aortic valve implantation (TAVI) systems to treat patients suffering from aortic valve disease. The Company’s transapical TAVI system is CE marked and currently marketed in Europe and other markets worldwide and its new transfemoral TAVI system is currently undergoing clinical evaluation in Europe with a view toward achieving CE Mark in 2015. JenaValve is backed by world-class U.S., European and Asian investors, including Atlas Venture, Edmond de Rothschild Investment Partners, GIMV, NeoMed Management, Legend Capital, VI Partners, Sunstone Capital, Omega Funds, Biovest and Valiance Advisors.